MedPath

Bariatric Surgery in Children.

Not Applicable
Conditions
Obesity, Morbid
Interventions
Procedure: laparoscopic adjustable gastric band
Behavioral: Combined life style interventions
Registration Number
NCT01172899
Lead Sponsor
Maastricht University Medical Center
Brief Summary

Rationale:

In the Western world overweight and obesity is an increasing problem both in adults and in children. In youth, it is associated with early death and a number of co-morbidities including metabolic and endocrine changes, increased inflammatory status, cardiovascular abnormalities, nonalcoholic fatty liver disease, and impaired quality of life.

The standard treatment for morbid obesity in children is by combined life style interventions. However, the medium and long term effects of dietetic interventions, behaviour therapy and medication is relatively poor. In adults bariatric surgery shows good results with up to 30% weight reduction in 3 years. The preliminary results in youth are similar, but surgery in this age group is relatively uncommon. In the Netherlands surgery in this age group is only allowed in clinical trials, until the benefits and risks have been established. (National Health Authorities)

Objective:

To determine if surgery gives a superior weight and body mass index (BMI) reduction than combined life style interventions in adolescents with morbid obesity and to assess its effect on obesity associated co-morbidity.

Study design:

Prospective randomised interventional study.

Study population:

Morbidly obese children, aged 14 - 16 years, with sex and age adjusted BMI \>40 kg/m2 or \>35 kg/m2 with co-morbidity.

Intervention:

Bariatric surgery by laparoscopic adjustable gastric band (LAGB) or combined life style interventions

Main study parameters/endpoints:

Primary endpoints: weight loss, loss of excess weight, loss of excess BMI. Secondary endpoints: Body composition, pubertal development, metabolic and endocrine changes, inflammatory status, cardiovascular abnormalities, non-alcoholic steatohepatitis, brain development, quality of life, and behaviour changes. The potential complications of surgery are monitored.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
60
Inclusion Criteria
  • Aged 14 to 16

  • Age and sex adjusted BMI >40 kg/m2 or >35 kg/m2 with associated co-morbidity.

    * Associated co-morbidity includes: glucose intolerance, type 2 diabetes, hypertension, pseudotumor cerebri, acanthosis nigricans, obstructive sleep apnoea syndrome, depression, arthropathies, non-alcoholic steatohepatitis and dyslipidemia.

  • > 1 year multidisciplinary organized weight reducing attempts with less than 5% weight loss

  • Demonstrate decisional capacity

Exclusion Criteria
  • Psychologically not suitable
  • Pre-menarche or bone age <15 years in boys
  • Obesity associated to other disorders such as hypothyroidism
  • Syndromal disorders such as Prader-Willi syndrome
  • Severe cardiorespiratory impairment (ASA class 3 or higher)
  • Insufficiently fluid in the Dutch language
  • Unwillingness to adhere to follow-up programmes

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Laparoscopic adjustable gastric bandlaparoscopic adjustable gastric band-
Laparoscopic adjustable gastric bandCombined life style interventions-
Control groupCombined life style interventions-
Primary Outcome Measures
NameTimeMethod
Weight36 months

Weight loss, excess weight loss and loss of excess BMI.

Secondary Outcome Measures
NameTimeMethod
Metabolic and endocrine changes36 months
Quality of life changes36 months
Behaviour changes36 months

Measuring impulsivity and positive reward dominance with a computer task.

Behavior towards food36 months

Behavior towards food is assessed by questionnaires and a computerized model for wanting and liking of food.

Effects on sleep architecture36 months
Body composition36 months

Next to anthropometric measurements, bone mineral content, bone density, lean bodymass and fat percentage will be assessed.

Non-alcoholic fatty liver disease36 months

Next to an ultrasound of the liver, serum levels of ALT, AST, ALP and GGT are measured. CCL-2 is used as a surrogate marker to assess liver disease.

Pubertal development36 months

Follow-up of hormonal status and Tanner stages.

Inflammatory status36 months

Measurement of serum inflammatory markers.

Cardiovascular abnormalities36 months
Operative complicationsup to 36 months

Early and late complications are being monitored

Brain development36 months

If extra sponsorship can be gained, we will use fMRI and MEG in a subgroup to measure blood oxygen level-dependent (BOLD) brain response to food stimuli.

Physical activity36 months

Assessment of physical activity using a questionnaire and an accelerometer.

Trial Locations

Locations (1)

Maastricht University Medical Center

🇳🇱

Maastricht, Limburg, Netherlands

© Copyright 2025. All Rights Reserved by MedPath